IASO Bio Wins the 'Oscar of Healthcare Innovation' — Qipu Award for Ixazomib-based CAR-T Therapy

Nov 25, 2024 17:55 CST Updated 17:55

IASO Biotechnology

Cancer Treatment New Drug Developer

Click to follow?｜Focus on Global Biomedical Investment

On November 24, the 2024 China Health Industry Innovation Summit and the 5th "Qipu Award" Ceremony was held in Shanghai. IASO Bio was recognized for its outstanding achievements."China's First BCMA-Targeted CAR-T Product, Ixcellen Injection, for the Treatment of Multiple Myeloma"Stand out in the fierce competition,Awarded the "2024 Pharmaceutical Innovation Qipu Award"!

Efung Capital Ruikang Fund participated in IASO Bio's C1 financing round in 2023.

IASO Bio Honored：

2024 CHIP AWARD FOR PHARMACEUTICAL INNOVATION

IASO Bio Attends the On-site Award Ceremony (Photo)

Known as the "Oscar Awards" of the healthcare industry, the "CHIP Award" is also celebrating its 10th anniversary this year. The award categories cover 10 sectors of the health industry: hospitals, primary care and physicians, privately-run medical institutions, pharmaceuticals, medical devices, in vitro diagnostics, health digital intelligence, health industry development, health policy, and health philanthropy & ESG. A panel of 100 experts will review and vote on the nominated awards.

China's First BCMA-Targeted CAR-T Product

Idecabtagene Vicleucel Injection for the Treatment of Multiple Myeloma

▷The world's first useFully Human Antibody Sequence-Based CAR-T Drug, which is also the first CAR-T drug in China that targets BCMA and features full-process autonomous production (including plasmids, viruses, and cells).

▷Fully Human AntibodyLow immunogenicity, significantly prolonging the persistence time in patients; The light and heavy chains of single-chain antibodies work synergistically to bind tightly to a single BCMA molecule, with kinetic properties similar to natural TCRs, providing optimal signaling for CAR-T, enhancing tumor-killing efficiency, and reducing exhaustion.

▷Lentivirus Production Process Technology：Using a serum-free process, the biological titer is no less than that of the lentiviral packaging process with serum, effectively avoiding allergic reactions, achieving self-sufficiency from virus to plasmid, and all are GMP.¹Level, solving the industry's bottleneck problems.

Note 1: GMP is the abbreviation for "Good Manufacturing Practice," mainly referring to the standards in pharmaceutical production and quality management.

About the Chi-Pu Award

China Healthcare Innovation Platform (CHIP, Qipu) was founded in 2014. "Qipu" originates from the poem by Sima Biao of the Western Jin Dynasty: "Bian He lies hidden in obscurity, who can attest to this rare jade?" symbolizing precious jade or extraordinary talent. The China Healthcare Industry Innovation "Qipu Award," which began in 2014, has now reached its tenth year. The "Qipu Award" is an accolade in China's broader health sector aimed at encouraging and recognizing innovative projects with economic and social significance that enhance commercial and societal value. Upholding principles of fairness, professionalism, and independence, the "Qipu Award" focuses on the intrinsic quality of the projects and has earned respect and recognition within the healthcare industry, being hailed as the "Oscar Award" of China's medical and healthcare sector.

About IASO Bio's Equecabtagene Autoleucel Injection

Equecabtagene Autoleucel Injection (Focasu®) is used to treat adult patients with relapsed or refractory multiple myeloma who have progressed after at least three prior lines of therapy (including at least one proteasome inhibitor and one immunomodulatory agent). It is the world’s first commercially available fully human CAR-T product, China’s first independently developed and fully in-house manufactured CAR-T product, and also the first CAR-T product approved in China for the treatment of multiple myeloma.

About IASO Bio

IASO Bio is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative cell therapies. With a foundation of innovation in the development of hematological tumor cell therapies and antibody drugs, the company has expanded into autoimmune diseases, possessing comprehensive capabilities across the entire process from early discovery, clinical development, regulatory submission, to commercial-scale production. IASO Bio currently has over 10 innovative drug candidates at various stages of development. Among them, the injectable Ixazomib (a fully human BCMA CAR-T product) has been approved for marketing by the National Medical Products Administration (NMPA) and has received authorization from the U.S. FDA to conduct registration clinical trials for the treatment of relapsed/refractory multiple myeloma. Leveraging its strong management team, innovative pipeline, in-house GMP manufacturing, and robust clinical development capabilities, IASO Bio aims to deliver transformative and curative therapies, bringing hope of a cure to patients in China and around the world. For more information, please visit the company's official website: www.iasobio.com or LinkedIn page: www.linkedin.com/company/iasobiotherapeutics.